viewGilead Sciences, Inc.

Gilead Sciences' remdesivir to be available for selected coronavirus patients in the UK

The drug is being used as emergency treatment in Japan and the US, while generic versions will be distributed in 127 countries

Gilead Sciences, Inc. - Gilead Sciences' remdesivir to be available for selected Covid-19 patients in the UK

Gilead Sciences Inc’s (NASDAQ:GILD) remdesivir will de administered to selected Covid-19 patients in the UK.

The Medicines and Healthcare Products Regulatory Agency granted on Tuesday temporary access to the drug, which is not approved in any country.

READ: Gilead Sciences' remdesivir to be distributed in 127 countries

The government said that treatment will be prioritised for patients likely to benefit the most due to limited supplies.

Remdesivir is currently being used in the US and in Japan as an emergency treatment, while Gilead agreed licensing agreements with five generic pharmaceutical manufacturers to supply in 127 countries earlier this month.

Three trials confirmed that it allows for a faster recovery in patients with severe symptoms, while other studies are ongoing to assess its safety and efficacy in treating coronavirus.

Shares in Gilead rose 1% to US$74.08 in premarket trading.

Quick facts: Gilead Sciences, Inc.

Price: 76.32 USD

Market: NASDAQ
Market Cap: $95.73 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Inspired Energy raises up to £35mln in placing and open offer and fully...

Inspired Energy PLC's (LON:INSE) Mark Dickinson speaks to Proactive after announcing they've raised £35mln and struck a deal to acquire the 60% of Ignite Energy that it does not already own. Dickinson says the acquisition will accelerate the group's organic growth in optimisation services. In an...

1 day, 19 hours ago

2 min read